Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8 + Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma

The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP). Using a database of 69 ESCC patients, we analyzed PD-L1 expression on tumor cell...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-08, Vol.39 (8), p.4539-4548
Main Authors: Fukuoka, Eiji, Yamashita, Kimihiro, Tanaka, Tomoko, Sawada, Ryuichiro, Sugita, Yutaka, Arimoto, Akira, Fujita, Mitsugu, Takiguchi, Gosuke, Matsuda, Takeru, Oshikiri, Taro, Nakamura, Tetsu, Suzuki, Satoshi, Kakeji, Yoshihiro
Format: Article
Language:English
Subjects:
5-Fluorouracil
Biopsy
CD8 antigen
Chemotherapy
Cisplatin
Density
Esophageal cancer
Esophagus
Immune system
Lymphocytes
Medical prognosis
PD-1 protein
PD-L1 protein
Squamous cell carcinoma
Tumor cells
Tumor-infiltrating lymphocytes
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP). Using a database of 69 ESCC patients, we analyzed PD-L1 expression on tumor cells (TCs) and immune cells (ICs), as well as the density of CD8 tumor-infiltrating lymphocytes (TILs) in pretreatment biopsy specimens-versus-surgical specimens after resection. We determined the prognostic significance of these factors. The fraction of ESCC containing ICs expressing PD-L1 and having a high CD8 TIL density was significantly increased after neoadjuvant treatment. However, PD-L1 expression on TCs or ICs, and CD8 TIL density, was not significantly associated with patient survival in ESCC patients. NAC-FP induced PD-L1 expression on ICs and CD8 TILs in ESCC patients. This finding suggests that PD-1/PD-L1 blockade could be combined with NAC-FP to treat ESCC patients.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13631